Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Cortech Inc.

(CRTQ)

Lind & Co. analyst Douglas Lind said CRTQ is a buying opportunity based on a

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE